股本结构
单位：万股
| 公告日期 | 2026-08-10 | 2026-07-15 | 2026-08-10 | 2026-06-24 | 2026-05-11 | 2026-05-11 |
|---|---|---|---|---|---|---|
| 证券总股本 | 8510.67 | 8411.54 | 8360.67 | 8261.54 | 7361.54 | 7213.41 |
| 普通股本 | 8510.67 | 8411.54 | 8360.67 | 8261.54 | 7361.54 | 7213.41 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2026-08-01 | 2026-07-14 | 2026-06-30 | 2026-06-25 | 2026-05-01 | 2026-03-31 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2026-08-10 | 8510.67 | 未披露 | 定期报告 | 2026-08-01 |
| 2026-07-15 | 8411.54 | 未披露 |
更多>>
The underwriters exercised the option in full and added 1,500,000 shares of the company's Ordinary Share
|
2026-07-14 |
| 2026-08-10 | 8360.67 | 未披露 |
更多>>
From March 31,2026 to June 30,2026
Issuance of Class A Ordinary Shares and Pre-Funded Warrants under the 2026 Offering, net of transaction costs
Issuance of Class A Ordinary Shares under the Sales Agreement, net of transaction costs
Options exercised under the Equity Incentive Plan
|
2026-06-30 |
| 2026-06-24 | 8261.54 | 未披露 |
更多>>
Common stock offered 9,000,000 shares by the company
|
2026-06-25 |
| 2026-05-11 | 7361.54 | 未披露 | 定期报告 | 2026-05-01 |
| 2026-04-21 | 7285.22 | 未披露 | 定期报告 | 2026-04-09 |
| 2026-04-21 | 7260.57 | 未披露 | 定期报告 | 2026-04-01 |
| 2026-05-11 | 7213.41 | 未披露 |
更多>>
From January 1, 2026 to March 31, 2026
Issuance of Restricted Stock Awards under the MoonLake Immunotherapeutics 2022 Equity Incentive Plan
Options exercised under the MoonLake Immunotherapeutics 2022 Equity Incentive Plan
Issuance of Class A Ordinary Shares, net of transaction costs
|
2026-03-31 |
| 2026-02-25 | 7172.79 | 未披露 | 定期报告 | 2026-02-01 |
| 2026-02-25 | 7137.36 | 未披露 |
更多>>
From January 1, 2025 to December 31, 2025
Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares
Options exercised and converted under the Employee Stock Option Plan, net of stamp duty fee
Options exercised under the MoonLake Immunotherapeutics 2022 Equity Incentive Plan
Issuance of Restricted Stock Awards under the MoonLake Immunotherapeutics 2022 Equity Incentive Plan
Issuance of Class A Ordinary Shares under the 2025 Offering, net of transaction costs
|
2025-12-31 |
| 2025-11-05 | 7137.36 | 未披露 |
更多>>
Class A Ordinary Share offered 7,142,857 shares by the company
|
2025-11-06 |
| 2025-11-05 | 6423.07 | 未披露 |
更多>>
From June 30, 2025 to September 30, 2025
Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares
Options exercised under the MoonLake Immunotherapeutics 2022 Equity Incentive Plan
|
2025-09-30 |
| 2025-08-05 | 6423.07 | 未披露 | 定期报告 | 2025-08-01 |
| 2025-05-12 | 6420.36 | 未披露 |
更多>>
From January 1, 2025 to March 31, 2025
Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares
Issuance of Restricted Stock Awards under the Equity Incentive Plan
Options exercised and converted under the Employee Stock Option Plan, net of stamp duty fee
|
2025-03-31 |
| 2025-02-26 | 6401.20 | 未披露 | 定期报告 | 2025-02-01 |
| 2025-02-26 | 6391.87 | 未披露 |
更多>>
From January 1, 2024 to December 31, 2024
Issuance of Class A Ordinary Shares, net of transaction costs
Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares
Options exercised under the Equity Incentive Plan
Cancellation of MoonLake Class C Ordinary Shares following an employee contract termination in MoonLake AG
|
2024-12-31 |
| 2024-11-07 | 6390.52 | 未披露 | 定期报告 | 2024-11-01 |
| 2024-11-07 | 6388.73 | 未披露 |
更多>>
From June 30, 2024 to September 30, 2024
Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares
Options exercised under the Equity Incentive Plan
|
2024-09-30 |
| 2024-08-07 | 6388.39 | 未披露 | 定期报告 | 2024-08-01 |
| 2024-05-07 | 6386.99 | 未披露 |
更多>>
From December 31, 2023 to March 31, 2024
Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares
Cancellation of MoonLake Class C Ordinary Shares following an employee contract termination in MoonLake AG
Issuance of Class A Ordinary Shares, net of transaction costs
|
2024-03-31 |
| 2024-02-29 | 6388.68 | 未披露 | 定期报告 | 2024-02-29 |
| 2024-02-29 | 6297.19 | 未披露 |
更多>>
From December 31, 2022 to December 31, 2023
Issuance of Class A Ordinary Shares, net of transaction costs
Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares
|
2023-12-31 |
| 2023-11-14 | 6244.60 | 未披露 | 定期报告 | 2023-11-01 |
| 2023-11-14 | 6244.60 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares
|
2023-09-30 |
| 2023-08-10 | 6244.60 | 未披露 |
更多>>
From March 31, 2023 to June 30, 2023
Issuance of Class A Ordinary Shares, net of transaction costs
Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares
|
2023-06-30 |
| 2023-04-26 | 5270.11 | 未披露 | 定期报告 | 2023-04-13 |
| 2023-03-20 | 5270.11 | 未披露 | 定期报告 | 2023-03-01 |
| 2022-11-14 | 5270.11 | 未披露 | 定期报告 | 2022-11-14 |
| 2022-04-11 | 5270.11 | 未披露 | 定期报告 | 2022-04-05 |
| 2022-05-16 | 1822.44 | 未披露 |
更多>>
From January 1, 2022 to March 31, 2022
Shares no longer subject to redemption
|
2022-03-31 |
| 2021-03-31 | 1480.50 | 未披露 |
更多>>
From August 13, 2020 to December 31, 2020
Sale of 11,500,000 Class A ordinary shares, net of underwriting discounts and offering costs
Sale of 430,000 Private Placement Shares
Class A ordinary shares subject to possible redemption
Issuance of Class B ordinary shares to Sponsor
|
2020-12-31 |
| 2020-12-03 | 1480.50 | 未披露 | 定期报告 | 2020-12-03 |
| 2020-10-21 | 1290.00 | 未披露 |
更多>>
1.Class A ordinary shares offered: 10,000,000 shares, at $10.00 per share.
|
2020-10-20 |
The underwriters exercised the option in full and added 1,500,000 shares of the company's Ordinary Share
From March 31,2026 to June 30,2026
Issuance of Class A Ordinary Shares and Pre-Funded Warrants under the 2026 Offering, net of transaction costs
Issuance of Class A Ordinary Shares under the Sales Agreement, net of transaction costs
Options exercised under the Equity Incentive Plan
Common stock offered 9,000,000 shares by the company
From January 1, 2026 to March 31, 2026
Issuance of Restricted Stock Awards under the MoonLake Immunotherapeutics 2022 Equity Incentive Plan
Options exercised under the MoonLake Immunotherapeutics 2022 Equity Incentive Plan
Issuance of Class A Ordinary Shares, net of transaction costs
From January 1, 2025 to December 31, 2025
Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares
Options exercised and converted under the Employee Stock Option Plan, net of stamp duty fee
Options exercised under the MoonLake Immunotherapeutics 2022 Equity Incentive Plan
Issuance of Restricted Stock Awards under the MoonLake Immunotherapeutics 2022 Equity Incentive Plan
Issuance of Class A Ordinary Shares under the 2025 Offering, net of transaction costs
Class A Ordinary Share offered 7,142,857 shares by the company
From June 30, 2025 to September 30, 2025
Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares
Options exercised under the MoonLake Immunotherapeutics 2022 Equity Incentive Plan
From January 1, 2025 to March 31, 2025
Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares
Issuance of Restricted Stock Awards under the Equity Incentive Plan
Options exercised and converted under the Employee Stock Option Plan, net of stamp duty fee
From January 1, 2024 to December 31, 2024
Issuance of Class A Ordinary Shares, net of transaction costs
Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares
Options exercised under the Equity Incentive Plan
Cancellation of MoonLake Class C Ordinary Shares following an employee contract termination in MoonLake AG
From June 30, 2024 to September 30, 2024
Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares
Options exercised under the Equity Incentive Plan
From December 31, 2023 to March 31, 2024
Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares
Cancellation of MoonLake Class C Ordinary Shares following an employee contract termination in MoonLake AG
Issuance of Class A Ordinary Shares, net of transaction costs
From December 31, 2022 to December 31, 2023
Issuance of Class A Ordinary Shares, net of transaction costs
Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares
From June 30, 2023 to September 30, 2023
Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares
From March 31, 2023 to June 30, 2023
Issuance of Class A Ordinary Shares, net of transaction costs
Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares
From January 1, 2022 to March 31, 2022
Shares no longer subject to redemption
From August 13, 2020 to December 31, 2020
Sale of 11,500,000 Class A ordinary shares, net of underwriting discounts and offering costs
Sale of 430,000 Private Placement Shares
Class A ordinary shares subject to possible redemption
Issuance of Class B ordinary shares to Sponsor
1.Class A ordinary shares offered: 10,000,000 shares, at $10.00 per share.